Trial Profile
Safety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 May 2022
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; LHRH receptor agonists; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Acronyms CARLHA
- 18 May 2022 Status changed from active, no longer recruiting to completed.
- 01 Feb 2022 Planned End Date changed from 1 Jan 2022 to 1 Mar 2022.
- 01 Feb 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Mar 2022.